IMPART

What IMPART does

IMPART is a national virtual research institute headquartered at Dalhousie Medicine New Brunswick in Saint John, New Brunswick. Founded in 2017 by Dr. Keith Brunt with Dr. Jean-François Légaré, it operates as a collaborative research network — not a standalone commercial entity — and reports an internal team of 5 supported by a broader affiliated network of 45 academic and clinical partners across 8 universities and 6 Canadian provinces, 25 community and funding-agency members, 15 private-sector representatives, and two provincial government departments.

The institute's research is structured around three pillars: Inflammation and Metabolism, Physical Ability, and Research Translation, with a primary focus on cardiovascular health, metabolism, and chronic disease (diabetes, obesity, COPD, frailty, and select cancers). Core technical assets include the CTRnet-certified IMPART Biobank of annotated human cardiac tissue and blood specimens located at Dalhousie Faculty of Medicine adjacent to Saint John Regional Hospital; the MyROaD training program offering multi-institutional lab exchanges and industry micro-credentials; the Vulnerability Index mobile app that scores patient vulnerability across eight social determinants of health; the IMPART Podcast; and CardioTalk, a cardiovascular research seminar series. Underlying laboratory capabilities span gene and protein therapy, biologics, nanopharmacology, immunotherapeutics, stem-cell therapy, biomaterials, and regenerative medicine.

IMPART is funded almost exclusively by Canadian public and charitable research grants (NSERC, CIHR, Heart and Stroke Foundation, Canadian Diabetes Association, New Brunswick Health Research Foundation, Dalhousie Medicine). It has no commercial pricing model, sells no products, and conducts no sales-led go-to-market; dissemination occurs through academic publications, the Vulnerability Index app, clinical practice adoption via the New Brunswick Heart Centre partnership, and technology commercialization via industry collaborators such as Cloud DX and NB-BioMatrix.

Name

IMPART

Legal name

Dalhousie Medicine New Brunswick

Website

https://impart.team

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

IMPART is a non-profit virtual research institute at Dalhousie Medicine New Brunswick that conducts collaborative cardiovascular and metabolic research and operates a CTRnet-certified cardiac biobank serving academic and clinical partners across Canada.

Ownership category

akta.pro rank

Product category

Medical Research (Cardiovascular and Metabolism)

NAICS

Other Scientific and Technical Consulting Services (54169), Educational Support Services (61171)

SIC

Services-Misc Health & Allied Services, Nec (8090), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)

akta.pro secondary industries

Clinical Research Support (CRC/CTA) (EDAOAJAO), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

Keywords

• Cardiovascular research services
• Biomedical research institute
• Biobank biorepository services
• Clinical research training
• Translational health research

Headquarters

HQ city

Saint John

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Grants and Funding: IMPART is supported by government research funding agencies including Natural Sciences and Engineering Research Council (NSERC), Canadian Institutes of Health Research (CIHR), and Dalhousie Medicine. The institute conducts collaborative research funded by various national and provincial research foundations.
2. Research Grants: Individual researchers receive grants from organizations such as Canadian Diabetes Association ($300,000 over 3 years for Dr. Pulinilkunnil), Heart and Stroke Foundation, New Brunswick Health Research Foundation, and other medical research foundations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

IMPART is a national virtual research institute that conducts fundamental, clinical, and translational research in cardiovascular health, metabolism, and chronic disease, organized around three core pillars: Inflammation & Metabolism, Physical Ability, and Research Translation. It operates the CTRnet-certified IMPART Biobank for human cardiac tissue samples, the MyROaD training program, the Vulnerability Index App for clinical vulnerability assessment, and supporting media properties (Podcast, CardioTalk, Research Reels). Research is delivered through a network of 45 academic and clinical partners across 8 universities and 6 Canadian provinces.

Product overview

IMPART is a national virtual research institute focused on fundamental, clinical, and translational research in inflammation, metabolism, physical ability, and research translation. The organization operates as a research collaboration rather than a commercial product company, offering research services including the IMPART Biobank for tissue sample storage, the MyROaD training program for researchers, a Vulnerability Index App for patient vulnerability assessment, the IMPART Podcast for patient stories, and CardioTalk for research presentations.

Differentiator

Problem solved

Functional benefit

Products and services

• IMPART Biobank A CTRnet-certified biorepository that collects, processes, and stores detailed annotated human heart samples, serum, plasma, and whole blood cells from volunteer participants undergoing cardiac surgery at the New Brunswick Heart Centre, with complete clinical data, serving cardiovascular researchers and the global scientific community.
• MyROaD Program (Maximize your Research on Obesity and Diabetes) A multi-institutional training program offering laboratory exchanges, EDI training, workshops on market commercialization, micro-credentialing, certification, internships among for-profit and non-profit industrial partners, and awards, designed for graduate and postdoctoral researchers in obesity and diabetes research.
• Vulnerability Index App A mobile application that helps physicians determine a patient's level of vulnerability using an algorithm based on eight social determinants of health (housing, income, food security, education and literacy, employment security, social support, personal health habits/coping skills, and family history) and connects patients with appropriate social agencies.
• IMPART Podcast A storytelling podcast featuring patient narratives and experiences navigating healthcare systems while living with diabetes, cardiovascular diseases, obesity, cancer, and other conditions, aimed at physicians, medical students, and healthcare professionals to initiate solution-oriented dialogue.
• CardioTalk A research presentation series through DalCREW that brings together local and international leaders in cardiovascular research for regular seminars, providing networking opportunities and a forum for trainees to present their research.

Quantifiable outcome

• Vulnerable populations (20% of NB population) represent 80% of healthcare costs ($2.75 billion budget)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• Dalhousie Medicine New BrunswickcoreStrategic or Co-development PartnerHost institution for IMPART located at Tucker Park campus in Saint John, NB. Provides infrastructure, faculty appointments, and administrative support for the research institute.
• New Brunswick Heart Centre (NBHC)coreStrategic or Co-development PartnerSurgical center where biobank samples are collected from consenting cardiac surgery patients. Surgeons and physicians seek patient consent for tissue collection during procedures.
• Cardiovascular Research New Brunswick (CVRNB)majorStrategic or Co-development PartnerCollaborating research organization that may request biobank samples and clinical data for cardiovascular research studies.
• Canadian Tumour Repository Network (CTRnet)coreTechnology or IntegrationNational network providing certification for the IMPART Biobank as a recognized biorepository meeting quality standards for tumour and tissue sample handling.
• NB-BioMatrix, Inc.majorStrategic or Co-development PartnerDr. Keith Brunt serves as Chief Scientific Officer. Company focuses on health technology innovations and medical device development.
• University of New BrunswickmajorStrategic or Co-development PartnerAcademic partner with faculty cross-appointments and collaborative research programs with IMPART investigators.
• University of GuelphmajorStrategic or Co-development PartnerAcademic partner with special graduate faculty membership and collaborative research including Dr. Jeremy Simpson and Dr. Glen Pyle.
• Cloud DXminorStrategic or Co-development PartnerHealth technology company whose Pulsewave wrist-worn blood pressure monitor was validated through IMPART-led clinical study at New Brunswick Heart Centre.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Peers

• Montreal Heart Institute (Institut de Cardiologie de Montréal):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/impartteam
• LinkedInlinkedin.com/company/impartnb

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMPART